【October 30th, 2020】
Genome Editing: What issues and how do we address them when bringing our developments to market? (tentative)
For commercialization and effective social mounting of genome-edited products, science-based and transparent regulation, IP environment which encourages more players to enter this field, and sound and unique ideas which link genomic information to diverse consumer value are indispensable. Last year, policies for handling genome edited organisms and food/feed products were finalized in Japan, and there is growing interest which genome-edited product would be first introduced to the market. However, still many people in industry concern about uncertainty which could be attributable to ambiguity and/or lack of information about regulation, IP environment and/or licensing policies, public acceptance, etc.
This online genome editing symposium will focus on such uncertainty and aim to share information required for social mounting of innovative ideas harnessing this groundbreaking technology.
|Title||Genome Editing: What issues and how do we address them when bringing our developments to market?
|Date||October 30 13:00 – 16:15 (Tokyo Time)|
|Holding method||Virtual Symposium|
|Organizer||Japan Society for Bioscience, Biotechnology and Agrochemistry (JSBBA)|
|Co-organizers||Cross-ministerial Strategic Innovation Promotion Program (SIP2)
Japan Bioindustry Association (JBA)
|Time table||Title (tentative)||Speaker|
|13:00 – 13:05||Opening Remarks||Minoru Yoshida
|13:05 – 13:35||CRISPR-Cas9 Intellectual Property for Innovations in Plant Agriculture: Corteva Agriscience’s Position and Joint Licensing Program||Trevor Jones & Mathias Müller
|13:35 – 14:05||Basic patents of genome editing technologies: challenges and opportunities in using them in agriculture.||Kazunori Hashimoto
Centcrest IP Attorneys
|14:05 – 14:35||Perspectives and things to consider on social mounting of genome-edited organisms and foods.||Manabu Takahara
|14:35 – 14:45||Break|
|14:45 – 15:15||New developments of gene-editing tool and strategies for their medical application.||Osamu Nureki
Tokyo University / Modalis Therapeutics
|15:15 – 15:45||Issues relating to industrialization of gene editing technologies (from academic point of view)||Takahiro Nakamura
|15:45 – 16:10||Discussion|
|16:10 – 16:15||Closing Remarks||Seiichi Toki